Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine

Vaccine

Volumn 29, Issue 45, 2011, Pages 8101-8107

  Gabitzsch, Elizabeth S ^a   Xu, Younong ^a   Balint, Joseph P ^a   Balcaitis, Stephanie ^a   Sanders Beer, Brigitte ^b   Jones, Frank R ^a  

^a Etubics Corporation   (United States)

^b BIOQUAL INC   (United States)

Author keywords

Ad5 E1 , E2b ; Ad5 immunity; Adenovirus vector; HIV vaccine

Indexed keywords

ADENOVIRUS SEROTYPE 5 VECTOR [E1 E2B]; ADENOVIRUS VECTOR; GAG PROTEIN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; POL PROTEIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE; MACACA MULATTA; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN IMMUNODEFICIENCY VIRUS;

ADENOVIRIDAE; ANIMALS; DRUG CARRIERS; FEMALE; GENE DELETION; GENE PRODUCTS, GAG; GENE PRODUCTS, NEF; GENE PRODUCTS, POL; GENETIC VECTORS; INTERFERON-GAMMA; LYMPHOCYTES; MACACA MULATTA; MALE; SAIDS VACCINES; VACCINES, SYNTHETIC;

EID: 80053619153     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.038     Document Type: Article

References (42)

1. Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 2007, 18:546-556.
2. Woolard S.N., Kumaraguru U. Viral vaccines and CTL response. J Biomed Biotechnol 2010, 141657. (Epub March 31, 2010).
3. Tatsis N., Ertl H.C. Adenoviruses as vaccine vectors. Mol Ther 2004, 10:616-629.
4. Gómez-Román V.R., Robert-Guroff M. Adenoviruses as vectors for HIV vaccines. AIDS Rev 2003, 5:178-185.
5. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-335.
6. Appaiahgari M.B., Saini M., Rauthan M., Jyoti, Vrati S. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect 2006, 8:92-104.
7. Barratt-Boyes S.M., Soloff A.C., Gao W., Nwanegbo E., Liu X., Rajakumar P.A., et al. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. J Gen Virol 2006, 87:139-149.
8. Cantanzaro A.T., Koup R.A., Roederrer M., Bailer R.T., Enama M.E., Moodic Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006, 194:1638-1649.
9. Tims T., Briggs D.J., Davis R.D., Xiang Z., Ertl H.C., Fu Z.F. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Vaccine 2000, 18:2804-2807.
10. Roberts D.M., Nanda A., Havenga M.J.E., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441:239-243.
11. Varnavski A.N., Zhang Y., Schnell M., Tazelaar J., Louboutin J.P., Yu Q.C., et al. Preexisting immunity to adenovirus in Rhesus monkeys fails to prevent vector-induced toxicity. J Virol 2002, 76:5711-5719.
12. Bangari D.S., Mittal S.K. Development of non-human adenoviruses as vaccine vectors. Vaccine 2006, 24:849-862.
13. Seregin S.S., Amalfitano A. Overcoming pre-existing adenovirus immunity by genetically engineering of adenovirus-based vectors. Expert Opin Biol Ther 2009, 9:1521-1531.
14. Gabitzsch E.S., Xu Y., Yoshida L.H., Balint J., Gayle R.B., Amalfitano A., et al. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant based vaccine used to induce cell mediated immune responses. Immunol Lett 2009, 122:44-51.
15. Amalfitano A., Hauser M.A., Hu H., Serra D., Begy C.R., Chamberlain J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998, 72:926-933.
16. Campos S.K., Barry M.A. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007, 7:189-204.
17. Amalfitano A., Begy C.R., Chamberlain J.S. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci USA 1996, 93:3352-3356.
18. Amalfitano A., Chamberlain J.S. Isolation and characterization of packaging cell lines that co-express the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther 1997, 4:258-263.
19. Hodges B.L., Serra D., Hu H., Begy C.A., Chamberlain J.S., Amalfitano A. Multiply deleted [E1-, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. J Gene Med 2000, 2:250-259.
20. Osada T., Yang X.Y., Hartman Z.C., Glass O., Hodges B.L., Niedzwiecki D., et al. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Can Gene Ther 2009, 16:673-682.
21. Gabitzsch E.S., Xu Y., Balint J.P., Hartman Z.C., Lyerly H.K., Jones F.R. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-,E2b-]-CEA. Cancer Immunol Immunother 2010, 59:1131-1135.
22. Gabitzsch E.S., Xu Y., Yoshida L.H., Balint J., Amalfitano A., Jones F.R. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 2009, 27:6394-6398.
23. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005, 5:201-214.
24. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., et al. Safety and immunogenicity of a replication-incompetent Adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008, 46:1769-1781.
25. Wiseman R.W., Karl J.A., Bimber B.N., O'Leary C.E., Lank S.M., Tuscher J.T., et al. Major histocompatibility complex genotyping with massively parallel pyrosequencing. Nat Med 2009, 15:1322-1326.
26. Mittereder N., March K.L., Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996, 70:7498-7509.
27. Cory A.H., Owen T.C., Barltrop J.A., Cory J.G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991, 3:207-212. 1991.
28. Hutnick N.A., Carnathan D., Ertl H., Betts M.R. Adenovirus-specfic human T cells are pervasive, polyfuntional, and cross reactive. Vaccine 2010, 28:1932-1941.
29. Miller J.D., van der Most R.G., Akindy R.S., Glidewell J.T., Albott S., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28:710-722.
30. Loffredo J.T., Sidney J., Bean A.T., Beal D.R., Bardet W., Wahl A., et al. Two MHC Class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. J Immunol 2009, 182:7763-7775.
31. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector-memory T cell responses are associated with protection of rhesus monkeys from mucosal SIV challenge. Nat Med 2009, 15:293-299.
32. McElrath M.J., DeRosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
33. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Lin S.w., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007, 81:6594-6604.
34. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.O., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003, 170:1416-1422.
35. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77:6305-6313.
36. Mast T.C., Kierstead L., Gupta S.B., Nikas A.A., Kallas E.G., Novitsky V., et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010, 28:950-957.
37. Tatsis N., Lasaro M.O., Lin S.W., Xiang Z.Q., Zhou D., DiMenna L., et al. Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol 2009, 182:6587-6599.
38. Harrer T., Harrer E., Kalams S.A., Elbeik T., Staprans S.I., Feinberg M.B., et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996, 12:585-592.
39. Giraldo-Vela J.P., Bean A.T., Rudersdorf R., Wallace L.T., Loffredo J.T., Erickson P., et al. Simian immunodeficiency virus-specific CD4+ T cells from successful vaccines target the SIV Gag capsid. Immunogenetics 2010, 62:701-707.
40. Gaufin T., Ribeiro R.M., Gautam R., Dufour J., Mandell D., Apetrei C., et al. Experimental depletion of CD8+ cells in acutely SIVagm-infected African Green Monkeys results in increased viral replication. Retrovirology 2010, 7:42.
41. Mullins R.M., Tovanabutra S., deCamp A.C., Frahm N., Gilbert P.B., Sanders-Buell E., et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011, 17:366-371.
42. Hu H., Serra D., Amalfitano A. Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther 1999, 10:355-364.